Dementia

• 1. Introduction

  ›

  Dementia affects more than 57 million people worldwide, and approximately 10 million new cases are diagnosed every single year. That works out to roughly one new case every three seconds. For those living with it, and for the families and caregivers around them, it reshapes every ordinary thing: a familiar street becomes a maze, a close relative's name slides out of reach, and eventually the act of swallowing a meal requires assistance. Yet dementia is not one disease. It is a syndrome, a collection of declining abilities, that can emerge from dozens of different underlying causes. What questions does that raise? Why do some people reach their nineties without any trace of it, while others show signs before they turn 50? What actually happens inside the brain? And why, despite decades of research, does no cure exist? The answers begin with the brain tissue of a 51-year-old woman named Auguste Deter, examined in Frankfurt in the early twentieth century.

• 2. What Dementia Actually Is

  ›

  Dementia is a syndrome, not a single disease, characterized by a general decline in cognitive processes that disrupts the ability to perform everyday activities. Memory problems are the most widely recognized feature, but they share the condition with difficulties in language, emotional regulation, reasoning, perception, and motivation. Neuropsychiatric symptoms, including agitation, hallucinations, delusions, and apathy, affect more than 90% of all dementia cases at some point, and they often appear before any obvious memory complaint.

  Motor changes accompany the cognitive ones. Paratonia, an inability to relax muscles, affects most people with dementia and in advanced stages can lead to fixed, contracted postures that cause skin breakdown, infection, and pain on movement. Changes in gait become a major source of falls. These motor impairments correlate closely with cognitive impairments and are a leading cause of disability and dependency.

  The condition is classified as ranging from mild to major, and progresses through broadly recognized stages. Early dementia allows most people to manage their affairs with modest help. The middle stage brings worsening memory, difficulty recognizing familiar people, and trouble holding conversations. In the late stage, 24-hour supervision becomes necessary; basic functions such as eating, swallowing, and continence are affected. Sleep disturbances worsen, and the person may no longer recognize faces they have known for decades. One phenomenon the source specifically notes is paradoxical lucidity, an unexpected transient recovery of mental clarity that can occur in some advanced cases, sometimes shortly before death.

• 3. The Many Faces of the Syndrome

  ›

  Alzheimer's disease accounts for 60-70% of dementia cases worldwide, making it by far the most common form. Its hallmark features are deposits of amyloid beta in extracellular plaques and neurofibrillary tangles formed by hyperphosphorylated tau proteins. These changes begin decades before symptoms appear; amyloid imaging can now detect them years, even decades, before the onset of any complaint. The medial temporal lobe, which houses the hippocampus, the amygdala, and the parahippocampal gyrus, is the earliest site of both atrophy and tau pathology.

  Vascular dementia is the second most common type, accounting for at least 20% of cases. It is caused by disease or injury affecting the blood supply to the brain, typically a series of mini-strokes. Where those strokes fall in the brain determines which symptoms appear; a single injury in the hippocampus or thalamus can cause sudden cognitive decline.

  Lewy body dementias include dementia with Lewy bodies and Parkinson's disease dementia. Up to 80% of people with dementia with Lewy bodies experience well-formed visual hallucinations, typically of people, animals, or children. The primary distinguishing sign is that Parkinson's disease precedes Parkinson's disease dementia by roughly a year. Abnormal sleep behaviors can begin before cognitive decline in dementia with Lewy bodies and are a core diagnostic feature.

  Frontotemporal dementias are notable because early memory problems are not their defining trait. Instead, drastic personality changes and language difficulties dominate. The behavioral variant typically affects people between the ages of 45 and 65, making it a young-onset dementia. Among its rarer subtypes is logopenic progressive aphasia, only formally identified in 2004, which features impaired repetition of words or phrases and difficulty retrieving words.

  Mixed dementia, the coexistence of more than one type, occurs in at least 10% of dementia cases. A 2025 NIH study acknowledged mixed dementia as the most common type overall, and it tends to progress more rapidly because more regions of the brain are simultaneously affected.

• 4. A History Written in Brain Tissue

  ›

  One of the earliest allusions to dementia in recorded history is attributed to the 7th-century BC Greek philosopher Pythagoras, who divided human life into six phases and described the final two as the "senium", a period of mental and physical decay. Around 550 BC, the Athenian statesman and poet Solon argued that a man's will could be invalidated if he showed loss of judgment due to advanced age. Plato held that the elderly should not be placed in positions of responsibility, while Aristotle saw mental decline as inevitable for anyone who grew old.

  The Roman statesman Cicero took a sharply different view, arguing that mental decline was not inevitable and affected only those who were "weak-willed." He maintained that remaining mentally active and eager to learn new things could stave off cognitive deterioration. His views were progressive, but they were largely ignored; for centuries, the medical world was dominated by Aristotle's writings, and physicians such as Galen simply repeated them.

  In Constantinople, Byzantine society went so far as to build special hospitals for people diagnosed with dementia or insanity. At least seven Byzantine emperors whose lifespans exceeded 70 years showed signs of cognitive decline, though their conditions could not be publicly acknowledged.

  The pivotal modern chapter opened in 1907, when Bavarian psychiatrist Alois Alzheimer examined the brain of Auguste Deter, a patient who had entered a Frankfurt mental hospital on the 25th of November 1901 at age 51. Deter had shown a striking cluster of symptoms: accusing her husband of adultery, neglecting household chores, struggling to write, and wandering wildly at night. Alzheimer agreed to continue her treatment in exchange for her medical records and the donation of her brain after her death. Deter died on the 8th of April 1906 from sepsis and pneumonia. Using the Bielschowsky stain method, then a new technique, Alzheimer observed senile plaques, neurofibrillary tangles, and atherosclerotic alteration. He presented his findings at a psychiatry conference in Tubingen on the 11th of April 1906, but his peers received the information poorly. By 1910, Alzheimer's teacher Emil Kraepelin published a book coining the term "Alzheimer's disease" to acknowledge the discovery's importance.

  For decades the condition remained poorly understood. By the 1970s, the medical community believed vascular dementia was rarer than previously thought and that Alzheimer's caused the vast majority of age-related mental impairments. Then in 1976, neurologist Robert Katzmann proposed that senile dementia occurring after 65 was pathologically identical to Alzheimer's occurring in younger people, and that if counted accurately, the disease was actually the fourth or fifth leading cause of death, though it was rarely recorded on death certificates.

• 5. Risk, Prevention, and the Modifiable Gap

  ›

  A 2017 global report identified nine risk factors for dementia, including lower levels of education, high blood pressure, hearing impairment, smoking, obesity, depression, physical inactivity, diabetes, and low social contact. Later updates in 2020 and 2024 added excessive alcohol use, traumatic brain injury, air pollution, untreated visual impairment, and high LDL cholesterol to that list. Researchers estimate that if all of these risk factors were addressed, nearly half of dementia cases could be prevented.

  Hearing loss alone may account for around 9% of dementia cases globally. The mechanism is partly straightforward: hearing loss promotes social isolation, and loneliness, distinct from mere social isolation, can increase the risk of dementia by one-third based on the English Longitudinal Study of Ageing. Living alone can double the risk of dementia, but having two or more closer relationships may reduce that risk.

  Physical activity, particularly aerobic exercise, is associated with a reduction in age-related brain tissue loss and neurotoxic factors. Multicomponent therapy combining aerobics, balance training, and strength training has been shown to improve independence in daily activities and reduce the risk of falls. The two risk factors researchers consider most modifiable are physical inactivity and lack of cognitive stimulation.

  Diet also plays a role. The Mediterranean diet and the DASH diet are both associated with less cognitive decline, and a combined approach called the MIND diet may be more protective still, though further study is needed. An economic model published in 2024 estimated that population-level interventions in England targeting high blood pressure, smoking, and obesity could save money and add healthy years of life. As one example, reducing salt in food to address hypertension could yield 39,433 quality-adjusted life-years and save 2.4 billion pounds.

  Age remains the greatest single risk factor, but the key distinction the source draws is this: dementia is not a normal part of aging. Many people aged 90 and above show no signs of it whatsoever.

• 6. Diagnosis and the Quest for Early Detection

  ›

  Diagnosing dementia depends on a combination of medical history, cognitive testing, imaging, and blood tests to rule out reversible causes such as hypothyroid conditions or vitamin deficiencies. The DSM-5, published by the American Psychiatric Association in 2013, sets the diagnostic criteria as a significant decline in one or more cognitive domains that interferes with everyday activities and is not explained by delirium or conditions such as major depressive disorder.

  Several brief cognitive tests running between five and fifteen minutes are widely used. The mini-mental state examination is the best studied and most commonly used. The Montreal Cognitive Assessment, freely available online in many languages, has been shown to be somewhat better at detecting mild cognitive impairment. An adapted version exists for people with hearing loss. A five-minute test called the integrated cognitive assessment (CognICA), delivered via a mobile app to an iPad, was given FDA approval in 2021 for commercial use as a medical device after being used in the UK.

  Before the early 2000s, a definitive Alzheimer's diagnosis could only be made from brain tissue examined after death. Since then, cerebrospinal fluid analysis has become available to detect Alzheimer's biomarkers, and blood-based biomarkers have now taken the lead. A finger-prick blood test using a protein marker called p-tau 217 has been developed for early Alzheimer's detection. Another protein called flotillin has been proposed as a potential fluid biomarker detectable in either cerebrospinal fluid or blood.

  Imaging has transformed both diagnosis and treatment development. PET scans using the radiotracer Pittsburgh compound B or florbetapir can show amyloid plaques years or decades before symptoms appear. Serial amyloid imaging traces how amyloid beta deposits spread: beginning in the anterior temporal areas, then moving into the frontal and medial parietal regions, then into the associative neocortex, and finally into the primary sensorimotor and subcortical regions. A tracer for tau protein called flortaucipir was approved for use in both the United States and Europe in 2024. These imaging advances made possible the development of anti-amyloid immunotherapies such as donanemab and lecanemab, approved for use in mild neurocognitive impairment due to Alzheimer's.

  One underappreciated risk window flagged in the source: in the first three months after a dementia diagnosis, and continuing for up to a year, the risk of suicide is significantly elevated, particularly among those diagnosed before the age of 65.

• 7. Care, Communication, and Carrying On

  ›

  No medication can halt the progression of dementia or reverse it. Donepezil, a cholinesterase inhibitor, provides small improvements in cognition and daily functioning for Alzheimer's patients, and rivastigmine is recommended for Parkinson's disease dementia. Memantine offers a small but consistent benefit for moderate-to-severe Alzheimer's. An extract of Ginkgo biloba called EGb 761, approved throughout Europe, is listed by the World Federation of Biological Psychiatry with the same level of evidence as acetylcholinesterase inhibitors; it is the only treatment that has shown symptom improvement in both Alzheimer's and vascular dementia.

  Antipsychotic medications carry serious risks for people with dementia. Severe and life-threatening reactions occur in almost half of people with Lewy body dementia, and a single dose can be fatal. Guidelines recommend attempting non-drug approaches first, and stopping antipsychotics generally does not cause problems even after long-term use.

  Non-pharmacological care carries some of the strongest evidence for improving quality of life. Music therapy with at least five sessions may reduce depressive symptoms and improve overall behaviors in institutionalized residents. In 2003, the Alzheimer's Society in the UK launched 'Singing for the Brain', a program of group singing of well-known songs combined with vocal exercises to support brain activity and well-being. Animal-assisted therapy, particularly with dogs, has been found helpful. Over 40% of people with dementia report sleep problems, and a 2012 recommendation from the American Geriatrics Society warned against benzodiazepines and non-benzodiazepine sleeping pills in this population because of increased risks of cognitive impairment, falls, and delirium.

  Nearly 80% of people with dementia in nursing homes may experience pain that is difficult for them to communicate, and that pain may be expressed only as a behavioral symptom. A tool called the Pain Assessment in Advanced Dementia scale is designed to help healthcare workers recognize it. Communication itself becomes one of the most demanding challenges as the condition advances. For people who have lost their speech, caregivers are advised to pay close attention to eye movements, facial expressions, and body language. In Japan, digital surveillance systems are in some places made available to family members when a person with dementia is prone to wandering and going missing.

• 8. Scale, Inequality, and the Road Ahead

  ›

  The number of people living with dementia worldwide was estimated at 57 million in 2021, with that figure projected to exceed 150 million by 2050. Almost half of all new cases occur in Asia. Europe accounts for roughly 25%, the Americas for 18%, and Africa for 8%. In Europe, Finland has the highest mortality rate from dementia in the world.

  The scale of inequality within the condition is striking. Two in three people with dementia are women, yet medical data from women are substantially less complete than data from men. Women are also more likely to take on caregiving roles, both in formal healthcare settings and informally. In low and middle income countries, the proportion of women caregivers is higher still.

  Racial and ethnic minorities face compounding disadvantages. They are often more affected by dementia risk factors such as high blood pressure, less likely to receive anti-dementia medications, and when medications are prescribed, less likely to adhere to them due to factors that include distrust of healthcare providers, stigma, and different cultural beliefs about the condition. In the United States, deaths from dementia tripled between 1999 and 2020, rising from around 150,000 to over 450,000, and the likelihood of dying from dementia increased across all demographic groups during that period.

  Social stigma compounds the inequality. People with dementia and their caregivers commonly report a perceived disparity in the care they receive compared with other serious conditions. Post-diagnostic support is often variable, and navigating available care options can be difficult. In some cities, access to care differs not just between rural and urban areas but between neighboring postcodes.

  The incidence of dementia increases exponentially with age, doubling with every 6.3-year increase. The median time from diagnosis to death ranges from 6.7 years for those diagnosed between the ages of 60 and 69, down to 1.9 years for those diagnosed at 90 or older. Against this backdrop, researchers continue to develop tools including the NODDI diffusion MRI technique for examining brain microstructure and tracking early neurodegeneration, pointing toward the possibility that the distance between an early warning sign and a meaningful clinical intervention may one day be measurably shorter.